Aindo

Aindo is an Italian startup founded at SISSA in 2018 that uses generative AI to create high-quality synthetic data for healthcare, life sciences, and finance. The company builds AI evidence infrastructure to help organizations generate evidence without compromising privacy or compliance. Their technology allows teams to analyze and share data securely while maintaining statistical and clinical value.

The business is primarily designed for researchers, clinicians, pharma & CROs, public administrations, and public healthcare institutions. It helps these organizations turn sensitive data into reliable evidence for better decisions and innovation. Their solutions are tailored to accelerate real-world evidence generation and clinical research.

To get started, interested parties can contact the team via email at [email protected] or by phone at +39 040 375 5640. They offer a contact form on their website where users can submit their name, company, email, and message to initiate a conversation with their experts.

The company is located at Località Padriciano 99, 34149, Trieste (TS), Italy, and operates out of Trieste and Milan. They have grown to a 25-person team across these two cities since their early recognition in 2020.

Aindo was founded in 2018 at the International School for Advanced Studies (SISSA) in Trieste. They launched as an AI consulting boutique focused on healthcare and finance before evolving into a European leader in synthetic data and AI evidence infrastructure.

The Trustburn rating is 4.1 out of 5 from 7 reviews, with the most recent feedback dated November 2023. The rating split includes five 5-star reviews, two 4-star reviews, and two 3-star reviews, all posted between January and November 2023.

Reviewers consistently praise Aindo's AI technology for being outstanding, top-notch, and impressive, helping streamline operations and automate business processes. They also highlight the team's professionalism, responsiveness, and willingness to go the extra mile to assist with needs.

Aindo offers several key services including synthetic data generation, real-world evidence creation, external control arms for clinical trials, and clinical intelligence through specialized language models. These tools help reduce bias, enrich datasets, and improve model performance by +7.1% sensitivity.

The company emphasizes compliance by design with certifications such as Europrivacy, ISO 9001, ISO 27001, and NIST cybersecurity standards. They are also GDPR-ready, EHDS-ready, and AI Act compliant, ensuring audit readiness and privacy-preserving AI practices.

Aindo differentiates itself by being the first company in Europe certified under Europrivacy for synthetic data in healthcare. They combine corporate experience with academic excellence from SISSA to build secure and interoperable health data ecosystems.

The process involves using cutting-edge generative AI to create high-quality synthetic cohorts that reflect real patient populations. This allows institutions to forecast demand, model scenarios, and measure performance without exposing patient-level data.

According to news articles, Aindo has been recognized for its innovative approach to healthcare data. They were selected for the European Data Incubator and joined Oxford's Creative Destruction Lab, gaining early recognition for their proof-of-concepts.

The company has secured competitive funding, including a €3M investment in 2021 and a €6M Series A led by United Ventures in 2023. They also received an Italian patent for their synthetic data technology and were named 'Best Startup in Industry' by Fortune Italia.

You can reach Aindo by phone at +390403755640 or by e-mail at info@aindo.ai.

The official website of Aindo is aindo.ai.